Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Der Urologe. Ausg. A
|
February 1, 2007
[Active studies of the AUO in 2007]
Heidrun Rexer
Aktuelle Urologie
|
November 30, 2021
Heidrun Rexer, Peter Hammerer
Aktuelle Urologie
|
May 21, 2021
Heidrun Rexer, Hubert Kübler, Margitta Retz
Aktuelle Urologie
|
July 28, 2021
Heidrun Rexer, Maria De Santis, Christian Doehn
Aktuelle Urologie
|
July 28, 2021
[Second/Third-Line Therapie nach Versagen von Docetaxel bei metastasiertem Prostatakarzinom (mCRPC)]
Heidrun Rexer, Marc-Oliver Grimm, Martin Bögemann
Deutsches Arzteblatt International
|
September 24, 2016
The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma
Christian Doehn, Viktor Grünwald, Thomas Steiner, et al.
Trials
|
October 6, 2017
Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
Carsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, et al.
Aktuelle Urologie
|
August 8, 2018
[Practice Pattern of Systemic Therapy for Urothelial Cancer in Germany - A Survey of the German Cancer Society]
Marie Christine Hupe, Axel S Merseburger, Maike de Wit, et al.
BJU International
|
September 24, 2013
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)
Susanne Krege, Heidrun Rexer, Frank vom Dorp, et al.
Prostate Cancer and Prostatic Diseases
|
April 17, 2022
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
Carsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Der Urologe. Ausg. A
|
February 1, 2007
[Active studies of the AUO in 2007]
Heidrun Rexer
Aktuelle Urologie
|
November 30, 2021
Heidrun Rexer, Peter Hammerer
Aktuelle Urologie
|
May 21, 2021
Heidrun Rexer, Hubert Kübler, Margitta Retz
Aktuelle Urologie
|
July 28, 2021
Heidrun Rexer, Maria De Santis, Christian Doehn
Aktuelle Urologie
|
July 28, 2021
[Second/Third-Line Therapie nach Versagen von Docetaxel bei metastasiertem Prostatakarzinom (mCRPC)]
Heidrun Rexer, Marc-Oliver Grimm, Martin Bögemann
Deutsches Arzteblatt International
|
September 24, 2016
The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma
Christian Doehn, Viktor Grünwald, Thomas Steiner, et al.
Trials
|
October 6, 2017
Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
Carsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, et al.
Aktuelle Urologie
|
August 8, 2018
[Practice Pattern of Systemic Therapy for Urothelial Cancer in Germany - A Survey of the German Cancer Society]
Marie Christine Hupe, Axel S Merseburger, Maike de Wit, et al.
BJU International
|
September 24, 2013
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)
Susanne Krege, Heidrun Rexer, Frank vom Dorp, et al.
Prostate Cancer and Prostatic Diseases
|
April 17, 2022
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
Carsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, et al.
Page
of 2